Clinical trial
A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
NCT03291249 is registered in ClinicalTrials.gov with Tiziana Life Sciences LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
- Lead sponsor
- Tiziana Life Sciences LTD
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- December 1, 2017
- Completion date
- June 1, 2019
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
nafld, nash - nonalcoholic steatohepatitis, t2dm (type 2 diabetes mellitus)